This could partly explain why the pharma stock Merck (NYSE: MRK) has rallied 21% year to date while the S&P 500 index has dropped 18% during that time. Last month, Merck reported results for the first quarter, ended March 31. For the quarter, Merck recorded $15.9 billion in net sales, which represented a 49.6% increase over the year-ago period.
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.